Saturday 17 October 2026
Export DRUG’s income statement to Excel — free account
Bright Minds Biosciences Inc.
DRUG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 67.9%, free cash flow fell 124.6% and total debt fell 84.7%, each against the same quarter a year earlier.
51.30
2.91
−5.37%
Follow DRUG
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
36.10 | 57.37 | 81.48 | 121.98 |
Net Debt/EBITDA |
14.54 | 12.93 | 20.24 | 26.97 | |
Debt/Assets |
0.05% | 0.02% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.29 | 0.77 | 0.89 | 3.42 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.12) | (0.54) | (0.71) | (0.60) | |
Cash per Share |
8.62 | 8.23 | 23.54 | 22.62 | |
Shareholders Equity per Share |
8.53 | 8.25 | 23.45 | 22.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.53 | 8.25 | 23.45 | 22.62 | |
Free Cash Flow |
(0.85) | (4.17) | (6.81) | (5.92) | |
Working Capital |
58.60 | 63.99 | 224.84 | 222.28 | |
Net Current Asset Value |
58.57 | 63.97 | 224.84 | 222.28 | |
| Other line items | |||||
Quick Ratio |
35.68 | 56.58 | 81.10 | 121.44 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.12) | (0.54) | (0.71) | (0.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.17 | 0.20 | 0.50 | 0.50 | |
Average Payables |
0.97 | 0.67 | 1.56 | 1.09 | |
Average Assets |
32.42 | 53.45 | 133.50 | 131.06 | |
Average Common Equity |
31.36 | 52.67 | 131.85 | 129.90 |
Columns are period end dates